Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (51)

Supplementary Figure 9. Difference in baseline maximum VAF for detected somatic alterations. Panel (a) shows the maximum VAF according to the response category in patients with evaluable disease in the overall cohort. Panel (b) shows further stratification according to the treatment subprotocol.

Year:

2025

Purpose: Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. Experimental Design: We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. Results: We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% ( n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. Conclusions: The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies. See related commentary by Russo et al., p. 4217

Year:

2025

Supplementary Table 9. Distribution of different genetic alterations according to response groups in different treatment arms. Shown in the table is the number of patients with molecular alteration in each response category.

Year:

2025

Supplementary Figure 8. Genomic alterations detected in patients treated in subprotocol Z1A enrolling patients with NRAS mutations who received treatment with binimetinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 6. Genomic alterations detected in patients treated in subprotocol S1 enrolling patients with NF1 mutations who received treatment with trametinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 2. Summary of genomic landscape in patients enrolled based on outside laboratory testing who had discordant mutations. Patients are stratified according to the site of tissue biopsy (primary or metastatic site). Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 7. Genetic alterations detected in patients treated in subprotocol W enrolling patients with FGFR pathway alterations who received treatment with AZD4547. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 4. Genomic alterations detected in patients treated in subprotocol I enrolling patients with PIK3CA mutations who received treatment with taselisib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 3. Genomic alterations detected in patients treated in subprotocol G enrolling patients with ROS1 translocations who received treatment with crizotinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (43)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard Yang

Assistant Professor, Molecular Genetic Pathology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Joseph Abi Jaoude

Stanford Health Care

UNITED STATES
View details

Aung Naing

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Roni Wilke

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sanghoon Lee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Gershenson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ruitao Lin

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Patricia LoRusso

Yale University

UNITED STATES
View details

Elizabeth Euscher

Professor

MD Anderson Cancer Center

UNITED STATES
View details

Yibo Dai

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ramez Kouzy

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Siqing Fu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yu Shyr

Professor and Chair

Vanderbilt University Medical Center

UNITED STATES
View details

Gwyn Richardson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ethan Ludmir

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan Sun

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pamela Soliman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

R. Tyler Hillman

Associate Professor

UC San Diego Health System

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Kai Wucherpfennig

Professor and Department Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shubham Pant

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Boruta

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Clifton D Fuller

Professor (Tenured)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details